Every material Form 8-K Evolus, Inc. has filed with the SEC since August 04, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Evolus reported third-quarter 2026 net revenue of $78.0 million, up 13% from a year earlier, and a GAAP operating loss of $8.4 million, narrowed from $11.5 million. The company reaffirmed its full-year 2026 net revenue outlook of $330 million to $337 million, while still reporting a net loss of $12.5 million for the quarter.
Q3 2026 net revenue of $78.0 million, up 13% from $69.0 million in Q3 2025
Adjusted EBITDA of $1.2 million, compared with a loss of $3.1 million in Q3 2025
Full-year 2026 net revenue guidance of $330 million to $337 million reaffirmed; non-GAAP operating expense guidance updated to $210 million to $213 million from $212 million to $216 million
Cash and cash equivalents of $41.7 million as of September 30, 2026, versus $45.2 million at June 30, 2026
Evolus reported second-quarter 2026 total net revenues of $84.1 million, up 21% from the prior year, and a net loss of $8.1 million, narrower than the $17.1 million loss a year earlier. The company raised its full-year 2026 net revenue guidance to $330 million to $337 million, lifting the low end of its prior $327 million to $337 million range, while its adjusted EBITDA reached $4.7 million, compared with a loss of $7.9 million a year earlier.
Q2 2026 total net revenues of $84.1 million, up 21% from $69.4 million in Q2 2025
Q2 2026 net loss of $8.1 million, or $0.12 per share, versus $17.1 million, or $0.27 per share, a year earlier
Full-year 2026 net revenue guidance raised to $330 million to $337 million from $327 million to $337 million
GAAP loss from operations of $4.5 million; cash and cash equivalents of $45.2 million as of June 30, 2026
Evolus Europe amended its December 20, 2023 license and distribution agreement with Symatese Aesthetics, adding Canada and Australia/New Zealand as territories and granting Evolus exclusive rights to commercialize the Estyme injectable hyaluronic acid gel line there. The filing gives Evolus payments of €920,000 upfront and up to an additional €1.38 million on regulatory approvals, with commercialization expected in 2028, so the financial commitment is modest and the effect on results depends on approvals and sales that are not yet quantified.
Upfront signing payments of €920,000, plus up to €1.38 million more on receipt of certain regulatory approvals
Initial term of 15 years for each new territory from first regulatory approval, with automatic five-year renewals
Symatese is responsible, at its expense, for development and regulatory work needed in the new territories
Commercialization in Canada, Australia and New Zealand is expected in 2028; the company cites a total addressable market of about $500 million annually for neurotoxins and dermal fillers in these markets
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Evolus, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →